Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
axitinib + etoposide
- Development stage
- Phase 2
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Axitinib + etoposide is an investigational combination therapy consisting of two small molecule drugs with distinct mechanisms of action. Axitinib is a potent and selective inhibitor of vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3), thereby blocking angiogenesis and tumor growth. Etoposide is a podophyllotoxin derivative that inhibits DNA topoisomerase II, leading to errors in DNA synthesis and apoptosis in cancer cells. This combination has been explored as an off-label regimen for relapsed or refractory brain tumors in pediatric patients, showing signals of efficacy particularly in medulloblastoma and atypical teratoid rhabdoid tumor (ATRT). The regimen typically uses metronomic dosing for etoposide alongside standard axitinib administration[1][2][3].
- Other names
- axitinib-etoposide combinationaxitinib and etoposide
02
Targets
ABCG2 (Breast cancer resistance protein)ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase)TOP2A (DNA topoisomerase II)TOP2B (DNA topoisomerase II beta)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)
Beyond the preview
Go deeper on axitinib + etoposide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on axitinib + etoposide.